RecruitingPhase 1Phase 2NCT07106580

Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Via Capsules for Intestinal Multidrug-resistant Bacteria Decolonization

A Monocentric, Prospective, Randomized, Placebo-controlled, Double-blinded Trial Investigating the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Capsules in Decolonization of Patients With Intestinal Carriage of Multidrug-resistant Organisms


Sponsor

University of Rijeka

Enrollment

48 participants

Start Date

Jul 28, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn if oral capsules containing lyophilized stool from healthy donors (fecal microbiota transplantation or FMT) can safely and effectively decolonize multidrug-resistant organisms (MDROs) from the intestines in adults. The main questions it aims to answer are: 1. Does FMT via oral capsules reduce or eliminate intestinal MDRO colonization? 2. What side effects or adverse events occur after taking FMT capsules? Researchers will compare FMT capsules to placebo capsules to see if FMT is effective and safe for decolonizing MDROs. Participants will: * Take either FMT capsules or placebo capsules by mouth * Attend 4 follow-up study visits over 6 months (180 days) for microbiological testing and safety monitoring * Provide stool samples and report any side effects


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • ≥ 18 years,
  • rectal swab positive for MDRO (including but not limited to: CRE, ESBL-E, VRE) within a week of randomization,
  • capable of swallowing oral capsules,
  • willing to give informed consent

Exclusion Criteria10

  • antibiotic treatment on the day of inclusion,
  • pregnant or breastfeeding, women of childbearing potential who are unwilling or unable to use an acceptable method of birth control,
  • patients with terminal diseases with expected life expectancy < 6 months,
  • unwillingness to ingest the capsules,
  • a history of colectomy, present colostomy or ileostomy,
  • patients with the diagnosis/treatment of inflammatory or functional bowel disease,
  • patients with malignant bowel diseases,
  • absolute neutrophil count < 500/mm3,
  • selective digestive decolonization with antibiotics within 6 months before randomization,
  • severe allergy to capsule components

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERlyophilized FMT capsules

A total of 18 capsules containing 3060 mg of lyophilizate given through 3 days (three capsules twice daily)

OTHERPlacebo capsules

18 capsules of identical appearance and weight given in the same way as FMT capsules


Locations(1)

Clinical Hospital Center Rijeka

Rijeka, Croatia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07106580


Related Trials